The Richmond, Va.-based company posted losses of $565,000, or 1¢ per share, on sales of approximately $2.5 billion for the three months ended September 30, seeing a 105.2% swing into the red while sales grew 5.6% compared with the previous year.
Adjusted to exclude one-time items, earnings per share were 32¢, down 20% from the same quarter last year but just in line with the 32¢ consensus on Wall Street, where analysts expected too see sales of $2.5 billion, which it also met.
“Our teams are working diligently to integrate the Halyard S&IP business and to address the continuing challenges we are facing in our domestic distribution business. The strategic moves we have made into attractive alternate sites of care with Byram, and in meaningfully building our own brand product portfolio with Halyard, have strengthened and diversified our business. These new businesses are helping to offset the continued pressures we face in our domestic distribution business,” prez & CEO P. Phipps said in an SEC filing.
Owens & Minor shifted its earning per share expectations for the full year to between $1.20 and $1.25.
“For 2018, our revised guidance range reflects lower year-to-date results and reduced expectations for our Global Solutions SBU. In addition, we expect Global Products’ production costs to be higher in the fourth quarter than in the third quarter. In light of this revised guidance range for 2018, we are re-evaluating our prior outlook for 2019 and anticipate issuing guidance for 2019 in the first quarter of next year. We remain focused on improving our operating performance and on executing our strategy to strengthen our company for the future,” CEO Phipps said in a prepared statement.
Shares in Owens & Minor have fallen approximately 41.6% today, at $8.30 as of 2:00 p.m. EDT.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.